Novo Nordisk

Who owns Novo Nordisk?
Novo Nordisk A/S is publicly traded on the New York Stock Exchange (NVO) and Nasdaq Copenhagen (NOVO-B). The Novo Nordisk Foundation, through its holding company Novo Holdings A/S, controls the majority of voting shares, making it the effective controlling shareholder. The foundation is one of the world's largest philanthropic foundations, with assets exceeding DKK 800 billion. Institutional investors hold the majority of publicly traded B shares, including Vanguard Group, BlackRock, and State Street Global Advisors.

Is Novo Nordisk publicly traded?
Yes, Novo Nordisk A/S is publicly traded on the New York Stock Exchange under ticker NVO and on Nasdaq Copenhagen under ticker NOVO-B. The company has been publicly listed for decades. The stock experienced significant volatility, losing nearly 50% of its value in the year preceding the 2026 guidance announcement, when it dropped 17% on the forecast of -5% to -13% adjusted sales growth.

What is Novo Nordisk's revenue?
Novo Nordisk reported FY2025 net sales of DKK 309 billion (approximately $44 billion), up 10% at constant exchange rates, with operating profit growth of 6%. For 2026, the company guides adjusted sales growth of -5% to -13% at constant exchange rates, reflecting pricing pressures including the USD 4.2 billion 340B Drug Pricing Program reversal, the MFN agreement with the US administration, reduced Medicaid coverage for obesity medications, and competition from Eli Lilly.

Who is the CEO of Novo Nordisk?
Mike Doustdar was appointed CEO in August 2025, succeeding Lars Fruergaard Jørgensen. Doustdar previously served as Executive Vice President and head of International Operations. The leadership change followed several profit downgrades and the company losing ground to US rival Eli Lilly. Doustdar faces the challenge of navigating what he described as a year of "unprecedented pricing pressure" while positioning the company for volume growth through lower prices and expanded access.

What is the Wegovy pill?
The Wegovy pill is the first oral GLP-1 receptor agonist tablet, launched in the US in January 2026. It contains semaglutide and is priced between $149 and $299 per month for cash payers, significantly lower than the injectable version. The pill reached 50,000 US prescriptions per week by late January 2026. The Wegovy pill provides a convenience advantage over injectable GLP-1 competitors and represents Novo Nordisk's strategy to expand access through lower pricing and easier administration.

When was Novo Nordisk founded?
Novo Nordisk's origins trace back to 1923, when the Nordic Insulin Laboratory was founded in Copenhagen by August Krogh, a Nobel Prize-winning professor, and his wife Marie Krogh, a physician with diabetes. In 1925, Thorvald Pedersen left Nordisk and founded Novo Terapeutisk Laboratorium, creating a competitor. The two companies merged in 1989 to form Novo Nordisk A/S, creating one of the world's largest diabetes care companies.

What is Novo Nordisk's competitive position?
Novo Nordisk is the global leader in diabetes care and one of two dominant players in the GLP-1 market, alongside Eli Lilly. The company faces intensifying competition from Eli Lilly's Mounjaro (diabetes) and Zepbound (obesity), which have gained market share. Novo Nordisk's next-generation candidate CagriSema reported disappointing results in late 2024, narrowing its pipeline advantage. The Wegovy pill launch in January 2026 provides a differentiation point as the first oral GLP-1 on the market.

What is the Novo Nordisk Foundation?
The Novo Nordisk Foundation is one of the world's largest philanthropic foundations, with assets exceeding DKK 800 billion. Through its holding company Novo Holdings A/S, the foundation controls the majority of voting shares in Novo Nordisk A/S, making it the effective controlling shareholder. The foundation's grants support scientific research, health programs, social causes, and humanitarian initiatives. This ownership model links Novo Nordisk's corporate profitability to societal benefit through the foundation's philanthropic activities.

Novo Nordisk's origins trace back to 1923, when the Nordic Insulin Laboratory (Nordisk Insulinlaboratorium) was founded in Copenhagen by August Krogh, a Nobel Prize-winning professor of physiology, and his wife Marie Krogh, a physician who had diabetes. The couple learned about insulin treatment during a visit to the United States and secured the rights to produce insulin in Scandinavia. Harald Pedersen, a pharmacist, and his brother Thorvald Pedersen joined the venture, with Harald responsible for insulin production and Thorvald for marketing.

In 1925, Thorvald Pedersen left Nordisk and founded Novo Terapeutisk Laboratorium, creating a competing insulin manufacturer. The two companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, operated as fierce competitors in the Danish insulin market for decades. Both companies grew internationally, establishing subsidiaries across Europe, the United States, and other markets.

In 1989, Novo and Nordisk merged to form Novo Nordisk A/S, creating one of the world's largest insulin and diabetes care companies. The merger combined Novo's expertise in enzyme production and insulin manufacturing with Nordisk's broader pharmaceutical portfolio. The merged company was listed on the Copenhagen Stock Exchange and later on the New York Stock Exchange.

Throughout the 1990s and 2000s, Novo Nordisk expanded its product portfolio beyond insulin, developing modern insulin analogues such as NovoRapid (NovoLog in the US), Levemir, and Tresiba. The company also pioneered GLP-1 receptor agonist technology, launching Victoza (liraglutide) in 2010 for type 2 diabetes.

In 2021, Novo Nordisk launched Wegovy (semaglutide for obesity) in the United States, following the success of Ozempic (semaglutide for diabetes), which was approved by the FDA in 2017. Wegovy became a major commercial success, transforming Novo Nordisk's business trajectory and making the company one of the most valuable in Europe. The GLP-1 receptor agonist market expanded rapidly, with Ozempic and Wegovy becoming widely prescribed for both diabetes and weight loss.

In 2025, Novo Nordisk reported total sales growth of 10% to DKK 309 billion, with operating profit growth of 6%. However, the company faced significant headwinds including pricing pressures from the US 340B Drug Pricing Program, intensifying competition from Eli Lilly's Mounjaro and Zepbound, and the loss of patent protection for semaglutide in certain markets. The company announced 9,000 job cuts and experienced several profit downgrades, leading to the CEO transition.

In August 2025, Mike Doustdar was appointed CEO. In January 2026, Novo Nordisk launched the Wegovy pill in the US, the first GLP-1 tablet on the market, priced between $149 and $299 per month for cash payers. The pill reached 50,000 US prescriptions per week by late January 2026.

In 2026, Novo Nordisk announced its 2026 outlook, forecasting adjusted sales growth of -5% to -13% at constant exchange rates. The company introduced new non-IFRS measures of adjusted sales growth and adjusted operating profit growth to exclude exceptional and non-recurring effects, primarily the USD 4.2 billion reversal of sales rebate provisions related to the 340B Drug Pricing Program. Despite the challenging outlook, Doustdar expressed confidence that the "painful" impact would be an "investment for our future," noting that the company is seeing a volume response to lower prices.

Novo Nordisk has committed to environmental sustainability targets, including carbon neutrality across its own operations (Scope 1 and 2) and science-based targets for Scope 3 emissions reduction. The company reports progress through CDP disclosures and publishes an annual ESG report aligned with Global Reporting Initiative standards. The company has invested in renewable energy for its manufacturing facilities, including the large-scale Kalundborg facility in Denmark.

Novo Nordisk does not hold B Corp certification. The company's sustainability reporting is independently assured by third-party auditors. The Novo Nordisk Foundation's philanthropic activities, funded by dividends from Novo Nordisk A/S, support scientific research, health programs, and humanitarian causes, representing a unique ownership model that links corporate profitability to societal benefit.

Novo Nordisk has faced significant scrutiny over drug pricing. The high cost of Wegovy in the United States (approximately $1,300 per month before insurance) has drawn criticism from patients, politicians, and healthcare advocates. The company's decision to launch the Wegovy pill at $149-$299 per month for cash payers represents a significant price reduction, but the injectable version remains expensive for many patients.

The 340B Drug Pricing Program has been a major source of controversy. The USD 4.2 billion reversal of sales rebate provisions in 2026 reflects a regulatory dispute over how drug manufacturers calculate rebates for safety-net hospitals and clinics. Novo Nordisk has been one of several pharmaceutical companies challenging the 340B program's implementation, and the financial impact has been significant.

The company has faced criticism over its environmental footprint. Semaglutide production requires significant quantities of high-grade ingredients, and the company has invested in expanding manufacturing capacity in Denmark and internationally. The construction of a new manufacturing facility in Kalundborg, Denmark, has been one of the largest industrial projects in Danish history, drawing both economic praise and environmental scrutiny.

Novo Nordisk has also faced questions about the long-term safety of GLP-1 receptor agonists. While the drugs have demonstrated significant weight loss and cardiovascular benefits, concerns have been raised about muscle loss, gastrointestinal side effects, and the need for continued use to maintain weight loss. The FDA has required post-marketing studies, and the company continues to monitor safety data.

The CEO transition in 2025 drew attention to the company's strategic challenges. Lars Fruergaard Jørgensen's departure after several profit downgrades and the loss of competitive ground to Eli Lilly raised questions about the company's ability to maintain its market leadership. The selection of Mike Doustdar, an internal candidate, signaled continuity rather than a dramatic strategic shift.